Insider Buying: Rhythm Pharmaceuticals Inc (RYTM) Director Buys 25,000 Shares of Stock
Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) Director David P. Meeker acquired 25,000 shares of the company’s stock in a transaction dated Tuesday, October 10th. The shares were bought at an average price of $17.00 per share, for a total transaction of $425,000.00. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Shares of Rhythm Pharmaceuticals Inc (RYTM) traded down 13.30% during trading on Tuesday, hitting $26.01. 695,874 shares of the stock traded hands. The firm’s market cap is $678.18 million. The company has a 50 day moving average price of $24.57 and a 200 day moving average price of $24.57. Rhythm Pharmaceuticals Inc has a 12 month low of $23.99 and a 12 month high of $26.50.
TRADEMARK VIOLATION WARNING: “Insider Buying: Rhythm Pharmaceuticals Inc (RYTM) Director Buys 25,000 Shares of Stock” was originally published by American Banking News and is the property of of American Banking News. If you are reading this news story on another site, it was stolen and republished in violation of US and international copyright & trademark laws. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/10/10/insider-buying-rhythm-pharmaceuticals-inc-rytm-director-buys-25000-shares-of-stock.html.
Rhythm Pharmaceuticals Company Profile
Rhythm Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. The Company’s lead peptide product candidate is setmelanotide, a potent, first-in-class melanocortin-4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity.
Receive News & Ratings for Rhythm Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.